Mostafavi F, Bahardoust M, Sera F, Amirabadizadeh A, Allahyari S, Ssentongod P
J Res Health Sci. 2024; 24(4):e00626.
PMID: 39431651
PMC: 11492529.
DOI: 10.34172/jrhs.2024.161.
Tunheim G, Fossum E, Robertson A, Ro G, Chopra A, Vaage J
BMC Infect Dis. 2024; 24(1):841.
PMID: 39164637
PMC: 11334563.
DOI: 10.1186/s12879-024-09670-w.
Mackin S, Sariol A, Diamond M
Immunol Rev. 2024; 328(1):205-220.
PMID: 39162394
PMC: 11661935.
DOI: 10.1111/imr.13383.
Giacomelli A, Ciubotariu C, Zacheo M, Rabbione A, Pieruzzi M, Barone F
Viruses. 2024; 16(7).
PMID: 39066168
PMC: 11281468.
DOI: 10.3390/v16071005.
Kassanjee R, Davies M, Heekes A, Mahomed H, Hawkridge A, Morden E
Vaccines (Basel). 2024; 12(6).
PMID: 38932357
PMC: 11209070.
DOI: 10.3390/vaccines12060628.
Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis.
Rahman M, Kamigaki T, Thandar M, Haruyama R, Yan F, Shibamura-Fujiogi M
BMJ Open. 2023; 13(12):e076892.
PMID: 38128943
DOI: 10.1136/bmjopen-2023-076892.
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).
Griessbach A, Chammartin F, Abela I, Amico P, Stoeckle M, Eichenberger A
Open Forum Infect Dis. 2023; 10(11):ofad536.
PMID: 38023564
PMC: 10655940.
DOI: 10.1093/ofid/ofad536.
Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.
Kislaya I, Sentis A, Starrfelt J, Nunes B, Martinez-Baz I, Nielsen K
Influenza Other Respir Viruses. 2023; 17(11):e13195.
PMID: 38019704
PMC: 10682901.
DOI: 10.1111/irv.13195.
Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Vaccination for Negative Conversion Time of Nucleic Acid in Nonsevere COVID-19 Patients Infected by SARS-CoV-2 Omicron Variant.
Zhu K, Ma S, Chen H, Xie J, Huang D, Hou Z
Int J Clin Pract. 2023; 2023:9576855.
PMID: 37790860
PMC: 10545465.
DOI: 10.1155/2023/9576855.
The role of vaccines in the COVID-19 pandemic: what have we learned?.
Krammer F
Semin Immunopathol. 2023; 45(4-6):451-468.
PMID: 37436465
PMC: 11136744.
DOI: 10.1007/s00281-023-00996-2.
Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022.
Blanquart F, Abad C, Ambroise J, Bernard M, Debarre F, Giannoli J
Int J Infect Dis. 2023; 133:89-96.
PMID: 37182550
PMC: 10176971.
DOI: 10.1016/j.ijid.2023.04.410.
Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy.
Stoddard M, Yuan L, Sarkar S, Mangalaganesh S, Nolan R, Bottino D
Vaccines (Basel). 2023; 11(4).
PMID: 37112718
PMC: 10140995.
DOI: 10.3390/vaccines11040806.
Value of Laboratory Indicators in Predicting Pneumonia in Symptomatic COVID-19 Patients Infected with the SARS-CoV-2 Omicron Variant.
Zhu K, Ma S, Chen H, Xie J, Huang D, Fu C
Infect Drug Resist. 2023; 16:1159-1170.
PMID: 36879854
PMC: 9985399.
DOI: 10.2147/IDR.S397231.
SARS-CoV-2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control.
Nielsen S, Alvarez J, Bicout D, Calistri P, Canali E, Drewe J
EFSA J. 2023; 21(2):e07822.
PMID: 36860662
PMC: 9968901.
DOI: 10.2903/j.efsa.2023.7822.
Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium.
Meurisse M, Catteau L, van Loenhout J, Braeye T, de Mot L, Serrien B
Vaccines (Basel). 2023; 11(2).
PMID: 36851257
PMC: 9961733.
DOI: 10.3390/vaccines11020378.
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
Munoz F, Sher L, Sabharwal C, Gurtman A, Xu X, Kitchin N
N Engl J Med. 2023; 388(7):621-634.
PMID: 36791162
PMC: 9947923.
DOI: 10.1056/NEJMoa2211031.
Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.
Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, Casado I, Navascues A, Burgui C
Euro Surveill. 2023; 28(5).
PMID: 36729113
PMC: 9896606.
DOI: 10.2807/1560-7917.ES.2023.28.5.2200337.
Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?.
Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A
Emerg Microbes Infect. 2023; 12(1):2174779.
PMID: 36715323
PMC: 9936995.
DOI: 10.1080/22221751.2023.2174779.
The clinical characteristics and risk factors for severe COVID-19 in patients with COVID-19 and tuberculosis coinfection.
Wang Y, Chen Y, Gu L, Lou L, Zhang J, Zhang K
Front Microbiol. 2023; 13:1061879.
PMID: 36619998
PMC: 9817148.
DOI: 10.3389/fmicb.2022.1061879.
Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study.
Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H
Open Forum Infect Dis. 2023; 9(12):ofac636.
PMID: 36589480
PMC: 9792082.
DOI: 10.1093/ofid/ofac636.
